NCT07421544尚未招募4 期
A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
Goldman, Butterwick, Fitzpatrick and Groff1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年3月1日最近更新:
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Physician Global Aesthetic Improvement Scale (PGAIS)
研究概览
简要总结
Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.
详细描述
100 patients total who demonstrate mild-to-moderate signs of facial aging, including volume loss, fine lines, and skin laxity will receive up to two treatments with Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid gel. Patients will return for follow up visits at day 14 and day 60 where they will undergo standardized 2D photography, VISIA photography and assessments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult subjects aged 30 to 75 years at the time of screening/baseline.
- •Fitzpatrick skin types I-VI.
- •Investigator classification of the subject as having mild-to-moderate facial aging in at least one (≥1) facial areas, defined as meeting the following scale criteria at screening/baseline:
- •Midface Volume Deficit Scale (Appendix A): score of 2-3 Nasolabial Folds Severity Scale (Appendix B): score of 2 or 3
- •Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.
- •Willing and able to provide written informed consent form and photography release for research, publication, and/or commercial use.
- •In good general health as determined by the investigator based on medical history and clinical judgment.
- •Willing to maintain the study-specified skincare regimen and refrain from initiating new topical or procedural facial treatments during the study period.
- •For subjects of childbearing potential, a negative urine pregnancy test at screening/baseline and at all subsequent visits, as applicable.
- •Female subjects of childbearing potential must agree to use an acceptable method of contraception throughout the study and must have been using systemic contraception consistently for at least 30 days prior to enrollment, unless they meet criteria for non-childbearing potential.
- •Subjects are considered not of childbearing potential if they meet one of the following:
- •History of hysterectomy or bilateral oophorectomy, or No menses for at least 12 consecutive months without an alternative medical cause.
- •Or, if of childbearing potential, must agree to use an effective form of contraception during the course of the study. Acceptable methods include:
- •Oral contraceptive pill, injection, implant, patch, vaginal ring, or intrauterine device (IUD) Intrauterine coil Bilateral tubal ligation Hysterectomy Barrier method used with an additional form of contraception (e.g., spermicide, sponge, or condom) Abstinence (must agree to use a barrier method if sexual activity begins during the study) Partner with a vasectomy (if not, subject must agree to use a barrier methods
排除标准
- •Prior use of injectable treatments to the face within the past 12 months, including HA fillers and biostimulator injectables, i.e. calcium hydroxyapatite, poly-L-lactic acid (e.g., Sculptra, Radiesse), platelet-rich plasma (PRP), platelet-rich fibrin (PRF) Any facial surgical procedure (e.g., facelift, facial implants) within the past 12 months.
- •Use of neuromodulators (e.g., botulinum toxin) to the face or neck within 6 months prior to study enrollment or at any time during the study period.
- •Use of dermal fillers of any kind during the study period.
- •Use of at-home energy-based devices intended for rejuvenation or fibroblastic/collagen stimulation within 30 days prior to treatment and during the study period.
- •Use of systemic retinoids (e.g., isotretinoin) within 3 months prior to enrollment
- •Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.
- •Plants to become pregnant during the study period, or current breastfeeding.
- •Known allergy or hypersensitivity to lidocaine, tetracaine, or other local anesthetics.
- •Coagulation disorders or use of anticoagulants or antiplatelet medications that cannot be safely discontinued per investigator discretion.
- •History of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma, dermatomyositis).
- •Current or recent use (within the past 3 months) of systemic immunosuppressive medications.
- •Any uncontrolled systemic condition that may increase risk or interfere with study participation, including but not limited to poorly managed diabetes, thyroid dysfunction, or cardiovascular disease.
- •Clinically significant neurological, psychological or psychiatric conditions, or any condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.
- •Current use of tobacco or nicotine-containing products, or use within 6 months prior to enrollment; participants must also agree to abstain from tobacco and nicotine-containing products for the duration of the study.
- •Participation in any other interventional clinical study within 30 days prior to enrollment or during the course of this study.
- •Unwillingness to refrain from undergoing any additional aesthetic treatments to the face and neck (e.g., lasers, injectables, energy-based devices, cosmeceuticals, etc.) from screening through the end of the study period.
- •Use of sunless tanner or have spray tanned in the treatment areas 4 weeks prior to study treatment.
- •History of keloids or scarring/tattoos in the treatment area.
研究组 & 干预措施
Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid
Experimental
Enrolled subjects will receive Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid
干预措施: Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (Other)
结局指标
主要结局
Physician Global Aesthetic Improvement Scale (PGAIS)
时间窗: Day 14 and Day 60
Circle One: 1. Very Much Improved 2. Much Improved 3. Improved 4. No Change 5. Worse
次要结局
- Subject Global Aesthetic Improvement Scale (SGAIS)(Day 14 and Day 60)
- Midface Volume Deficit Scale(Baseline, Day 14, Day 60)
- Nasolabial Folds Wrinkle Severity Rating Scale(Baseline, Day 14, Day 60)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Single vs Triple Hyaluronic Acid in Knee OsteoarthritisOsteoarthritis, KneeNCT07352540University of Erlangen-Nürnberg Medical School46
尚未招募
不适用
Efficacy of Microneedling With Hyaluronic Acid Injection for Gingival Augmentation in Thin Gingival PhenotypeNCT07317856University of Baghdad20
尚未招募
4 期
Effectiveness of a Sodium Hyaluronate 0.01% and Sh-Oligopeptide-85 SP Mouthwash for the Treatment of Symptomatic Oral Lichen PlanusOral Lichen PlanusNCT07280442Universidad Complutense de Madrid40
已完成
不适用
Post-market Study on BtHCROSS® for Restoring Facial Volume After a Single InjectionNCT07301619i+Med S.Coop.203
招募中
3 期
Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)NCT07346859Biopharma Plasma LLC56